Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perineural vs systemic dexmedetomidine as adjuvant to ropivacaine for ulnar nerve block
2016-004883-20Phase 2Completed
- Sponsor
- Ole Mathiesen
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmedetomidine in postoperative pain and musculoskeletal condition (MSK) (4 arms), sponsored by Ole Mathiesen. Primary endpoint: Duration of sensory nerve block (groups A, B, C). Started Dec 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative painmusculoskeletal condition (MSK)
Beyond the preview
Go deeper on 2016-004883-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004883-20.